Phase I DREAMM-9 Study of Belantamab Mafodotin + VRd in ASCT-Ineligible Newly Diagnosed MM

December 11-14, 2021; Atlanta, Georgia
The safety profile of belantamab mafodotin plus VRd for patients with newly diagnosed MM who are not eligible for ASCT was similar to the known safety of single-agent belantamab mafodotin in patients with R/R MM.
Format: Microsoft PowerPoint (.ppt)
File Size: 497 KB
Released: December 16, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
AstraZeneca
Daiichi Sankyo, Inc.
GlaxoSmithKline
Incyte Corporation
Jazz Pharmaceuticals, Inc.
Merck Sharp & Dohme Corp.
Novartis Pharmaceuticals Corporation

Related Content

Dr Jeff Sharman provides expert insight into the optimal treatment combinations in the management of CLL/SLL, from Clinical Care Options (CCO)

Jeff Sharman, MD Released: November 22, 2022

Video featuring an expert discussion of BTK inhibitors for CLL and MCL, from Clinical Care Options (CCO)

Matthew S. Davids, MD, MMSc Anthony Mato, MD, MSCE Jeff Sharman, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: November 22, 2022 Expired: November 21, 2023

Expert slides on nursing care for patients receiving CAR T-cells, including managing acute and long-term toxicities, from Clinical Care Options (CCO)

person default Kathryn Ciccolini, DNP, AGACNP-BC, OCN Linda Ramsdell, MSN, FNP-BC, OCN Released: November 17, 2022

Expert commentary on data from the SOHO 2022 Annual Meeting on BTK inhibitors for CLL and MCL, from Clinical Care Options (CCO)

Christopher R. Flowers, MD, MS Kami Maddocks, MD Released: November 16, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings